PatientsVille.com Logo

ANOREXIA and Oxycontin

PatientsVille

ANOREXIA Symptoms and Causes

Eating disorders are serious behavior problems. They can include severe overeating or not consuming enough food to stay healthy. They also involve extreme concern about your shape or weight.

Types of eating disorders include

  • Anorexia nervosa, in which you become too thin, but you don't eat enough because you think you are fat
  • Bulimia nervosa, which involves periods of overeating followed by purging, sometimes through self-induced vomiting or using laxatives
  • Binge-eating, which is out-of-control eating

Women are more likely than men to have eating disorders. They usually start in the teenage years and often occur along with depression, anxiety disorders, and substance abuse.

Eating disorders can lead to heart and kidney problems and even death. Getting help early is important. Treatment involves monitoring, talk therapy, nutritional counseling, and sometimes medicines.

NIH: National Institute of Mental Health

Check out the latest treatments for ANOREXIA

ANOREXIA treatment research studies

Oxycontin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Oxycontin Side Effects

Anxiety (606)
Pain (554)
Depression (486)
Nausea (432)
Overdose (409)
Constipation (367)
Back Pain (360)
Death (321)
Arthralgia (314)
Vomiting (309)
Substance Abuse (306)
Headache (292)
Asthenia (278)
Diarrhoea (272)
Inadequate Analgesia (270)
Abdominal Pain Upper (251)
Abdominal Pain (238)
Polysubstance Abuse (233)
Coma (231)
Somnolence (227)
Confusional State (208)
Malaise (205)
Agitation (189)
Hyperhidrosis (180)
Accidental Overdose (180)
Chest Pain (174)
Product Formulation Issue (174)
Insomnia (170)
Loss Of Consciousness (167)
Amnesia (165)
Fall (159)
Dyspnoea (157)
Suicidal Ideation (152)
Anorexia (140)
Chills (140)
Dizziness (138)
Aggression (136)
Feeling Abnormal (125)
Euphoric Mood (124)
Decreased Appetite (123)
Condition Aggravated (123)
Fatigue (121)
Anger (121)
Completed Suicide (120)
Abdominal Discomfort (113)
Road Traffic Accident (113)
Blood Pressure Increased (112)
Lethargy (109)
Pruritus (102)
Myocardial Infarction (97)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

ANOREXIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Lung Function Tests in Adolescents With Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention:
Outcome Measures: Lung function tests at admission of adolescents with Anorexia nervosa;   Lung function tests at discharge of adolescents with Anorexia nervosa
2 Recruiting Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa
Condition: Anorexia
Interventions: Procedure: Deep Brain Stimulation(DBS);   Procedure: Capsulotomy
Outcome Measure: Anorexia Related Preoccupations and Rituals
3 Recruiting Treatment of Anxiety and Anorexia Nervosa in Adolescents
Conditions: Anxiety;   Anorexia Nervosa
Interventions: Drug: Fish oil;   Procedure: Massage therapy;   Drug: Placebo pill
Outcome Measures: Tolerability of fish oil supplementation in adolescents with Anorexia nervosa.;   Improvement in trait anxiety in subjects receiving a combination of omega-3 PUFA supplementation and massage therapy plus standard of careas compared to subjects receiving standard of care treatment alone (controls).
4 Recruiting Anorexia Nervosa Genetics Initiative
Condition: Anorexia Nervosa
Intervention:
Outcome Measure: Genetic differences
5 Recruiting Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa
Conditions: Anorexia;   Generalized Anxiety
Intervention:
Outcome Measure: The primary outcome variable is startle response (eye blink).
6 Unknown  Paullinia Cupana for Anorexia in Oncologic Patients
Conditions: Cancer-related Problem/Condition;   Anorexia;   Loss of Weight
Intervention: Drug: Paullinia cupana
Outcome Measures: weight;   quality of life
7 Recruiting Pilot Study of Deep Brain Stimulation for Severe Anorexia Nervosa
Condition: Severe Intractable Anorexia Nervosa
Intervention: Device: Deep Brain Stimulation to nucleus accumbens/anterior limb of internal capsule
Outcome Measures: Adverse events associated with surgery or stimulation;   Eating Disorder pathology;   Eating Disorder Pathology;   Comorbid psychiatric symptoms;   Food Reward processing;   Habit formation (adapted 'fabulous fruit task');   MEG 'Resting State Network';   White matter integrity-DTI;   Habit formation(noise avoidance task)
8 Recruiting Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention: Dietary Supplement: fatty acids preparation- eye-q
Outcome Measures: Omega-3 fatty acids are superior to placebo in increasing BMI at day 70 compared with baseline;   reducing EAT -26;   changes in CGI;   change in HDRS;   changes in BDI;   changes in YBOCS;   adverse events;   clinical laboratory tests
9 Recruiting Bone Loss in Patients With Anorexia Nervosa
Condition: Patients With Anorexia Nervosa
Interventions: Other: clinical parameters description;   Other: para clinical parameters description;   Other: hormonal parameters dosing;   Other: bone modeling markers dosing
Outcome Measures: Dual-X-ray absorptiometry (DEXA);   Biological parameters identification;   clinical parameters identification
10 Recruiting IGF-1 and Bone Loss in Women With Anorexia Nervosa
Conditions: Anorexia Nervosa;   Osteopenia;   Osteoporosis
Interventions: Drug: rhIGF-1;   Drug: Risedronate;   Drug: Placebo
Outcome Measures: Bone Mineral Density;   Bone Microarchitecture and strength
11 Recruiting Cognitive Remediation Therapy in Anorexia Nervosa
Conditions: Adolescent;   Young Adult;   Hospitalised;   Anorexia Nervosa (DSM-IV Revised Criteria)
Interventions: Behavioral: Cognitive Remediation Therapy;   Behavioral: Sham Therapy
Outcome Measures: Neuropsychological functioning:Wisconsin Sorting Card Test (WSCT);   Clinical status Evaluation:Morgan and Russell Global Outcome Assessment Scale (GOAS);;   Central coherence;   Nutritional status;   Self-reported eating disorders symptoms;   Self-reported Cognitive style;;   Self-reported treatment satisfaction;   Self-reported motivation to change;   Self-reported self-esteem;   Flexibility evolution : Trail Making Test (TMT)
12 Recruiting Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone
Conditions: Anorexia Nervosa;   Catch- Down or Even an Interruption of Growth,;   Delayed Puberty;   Osteopenia With Failure of Acquisition of Bone Mass
Interventions: Drug: SOMATROPINE* : Norditropine® simplexx®;   Biological: Placebo
Outcome Measures: the growth-velocity;   growth-velocity;   Body composition;   Psychological changes
13 Unknown  Drug Transport in Patients With Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention:
Outcome Measure:
14 Recruiting UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa
Condition: Anorexia Nervosa
Interventions: Behavioral: UCAN+CBT;   Behavioral: CBT
Outcome Measures: Change in Body Mass Index (BMI) from baseline through 12 month follow-up;   Change in Global Eating Disorder Examination (EDE) Scores from baseline through 12 month follow-up;   Dropout (the percentage of individuals who withdrew participation from treatment);   Treatment satisfaction scores as measured with the Client Satisfaction Questionnaire (CSQ);   Relationship satisfaction as measured with the Dyadic Adjustment Scale (DAS) and DAS-4
15 Recruiting The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Conditions: Anorexia Nervosa;   Osteoporosis
Interventions: Drug: Teriparatide;   Drug: Placebo
Outcome Measure: Bone metabolism
16 Recruiting Effects of Anorexia Nervosa on Peak Bone Mass
Condition: Anorexia Nervosa
Interventions: Drug: RhIGF-1 with transdermal 17-beta estradiol;   Drug: Placebo and transdermal 17-beta estradiol
Outcome Measures: A significant increase in bone density over a 12-month period;   A significant improvement in bone microarchitecture parameters at the ultradistal radius and tibia over a 12-month period
17 Recruiting Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa
Condition: Anorexia Nervosa
Interventions: Drug: RM-131;   Drug: Placebo
Outcome Measures: Effect of RM-131 on body weight;   Effect of RM-131 on gastric emptying time;   Effect of RM-131 on appetite
18 Not yet recruiting Body Image Therapy in Anorexia Nervosa
Condition: Anorexia Nervosa
Interventions: Behavioral: Anamorphic Micro software;   Behavioral: therapy as usual
Outcome Measure: Body Shape Questionnaire
19 Recruiting Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
Condition: Anorexia Nervosa
Interventions: Drug: Olanzapine;   Drug: Placebo
Outcome Measures: Rate of Weight Gain;   Psychological Improvement
20 Recruiting Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa
Condition: Anorexia Nervosa
Intervention: Behavioral: RePAN
Outcome Measures: Body Mass Index (BMI);   Eating disorder Examination (EDE)